Malaria Vaccine Highly Protective in Early Trial

Researchers announced results from a Phase 1 clinical trial of Sanaria’s PfSPZ Vaccine to combat malaria. The PfSPZ Vaccine consists of live, weakened, purified malaria parasites that do not cause illness.

The trial included 40 adult volunteers, 20–44 years old, who were enrolled, vaccinated, and assessed by the principal investigator, Robert Seder, MD, and colleagues at the Vaccine Research Center, NIAID, NIH, Bethesda, MD. 

Volunteers received intravenous injections of the PfSPZ Vaccine. None of the six volunteers who received the highest dosage developed malaria after being bitten by malaria parasiteinfected (disease transmitting) mosquitoes. 

These results demonstrate that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites, a malaria parasite that causes more than 600,000 deaths annually.

Future clinical trials of the PfSPZ Vaccine are expected to occur in Africa, the U.S., and Europe.

For more information call (301) 770-3222 or visit